Cargando…
Decreased functional activity of multidrug resistance protein in primary colorectal cancer
BACKGROUND: The ATP-Binding Cassette (ABC)-transporter MultiDrug Resistance Protein 1 (MDR1) and Multidrug Resistance Related Protein 1 (MRP1) are expressed on the surface of enterocytes, which has led to the belief that these high capacity transporters are responsible for modulating chemosensitvity...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4415444/ https://www.ncbi.nlm.nih.gov/pubmed/25885226 http://dx.doi.org/10.1186/s13000-015-0264-6 |
_version_ | 1782369076222361600 |
---|---|
author | Micsik, Tamás Lőrincz, András Mersich, Tamás Baranyai, Zsolt Besznyák, István Dede, Kristóf Zaránd, Attila Jakab, Ferenc Szöllösi, László Krecsák Kéri, György Schwab, Richard Peták, István |
author_facet | Micsik, Tamás Lőrincz, András Mersich, Tamás Baranyai, Zsolt Besznyák, István Dede, Kristóf Zaránd, Attila Jakab, Ferenc Szöllösi, László Krecsák Kéri, György Schwab, Richard Peták, István |
author_sort | Micsik, Tamás |
collection | PubMed |
description | BACKGROUND: The ATP-Binding Cassette (ABC)-transporter MultiDrug Resistance Protein 1 (MDR1) and Multidrug Resistance Related Protein 1 (MRP1) are expressed on the surface of enterocytes, which has led to the belief that these high capacity transporters are responsible for modulating chemosensitvity of colorectal cancer. Several immunohistochemistry and reverse transcription polymerase chain reaction (RT-PCR) studies have provided controversial results in regards to the expression levels of these two ABC-transporters in colorectal cancer. Our study was designed to determine the yet uninvestigated functional activity of MDR1 and MRP1 transporters in normal human enterocytes compared to colorectal cancer cells from surgical biopsies. METHODS: 100 colorectal cancer and 28 adjacent healthy mucosa samples were obtained by intraoperative surgical sampling. Activity of MDR1 and MRP1 of viable epithelial and cancer cells were determined separately with the modified calcein-assay for multidrug resistance activity and sufficient data of 73 cancer and 11 healthy mucosa was analyzed statistically. RESULTS: Significantly decreased mean MDR1 activity was found in primary colorectal cancer samples compared to normal mucosa, while mean MRP1 activity showed no significant change. Functional activity was not affected by gender, age, stage or grade and localization of the tumor. CONCLUSION: We found lower MDR activity in cancer cells versus adjacent, apparently, healthy control tissue, thus, contrary to general belief, MDR activity seems not to play a major role in primary drug resistance, but might rather explain preferential/selective activity of Irinotecan and/or Oxaliplatin. Still, this picture might be more complex since chemotherapy by itself might alter MDR activity, and furthermore, today limited data is available about MDR activity of cancer stem cells in colorectal cancers. VIRTUAL SLIDES: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1675739129145824 |
format | Online Article Text |
id | pubmed-4415444 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-44154442015-05-01 Decreased functional activity of multidrug resistance protein in primary colorectal cancer Micsik, Tamás Lőrincz, András Mersich, Tamás Baranyai, Zsolt Besznyák, István Dede, Kristóf Zaránd, Attila Jakab, Ferenc Szöllösi, László Krecsák Kéri, György Schwab, Richard Peták, István Diagn Pathol Research BACKGROUND: The ATP-Binding Cassette (ABC)-transporter MultiDrug Resistance Protein 1 (MDR1) and Multidrug Resistance Related Protein 1 (MRP1) are expressed on the surface of enterocytes, which has led to the belief that these high capacity transporters are responsible for modulating chemosensitvity of colorectal cancer. Several immunohistochemistry and reverse transcription polymerase chain reaction (RT-PCR) studies have provided controversial results in regards to the expression levels of these two ABC-transporters in colorectal cancer. Our study was designed to determine the yet uninvestigated functional activity of MDR1 and MRP1 transporters in normal human enterocytes compared to colorectal cancer cells from surgical biopsies. METHODS: 100 colorectal cancer and 28 adjacent healthy mucosa samples were obtained by intraoperative surgical sampling. Activity of MDR1 and MRP1 of viable epithelial and cancer cells were determined separately with the modified calcein-assay for multidrug resistance activity and sufficient data of 73 cancer and 11 healthy mucosa was analyzed statistically. RESULTS: Significantly decreased mean MDR1 activity was found in primary colorectal cancer samples compared to normal mucosa, while mean MRP1 activity showed no significant change. Functional activity was not affected by gender, age, stage or grade and localization of the tumor. CONCLUSION: We found lower MDR activity in cancer cells versus adjacent, apparently, healthy control tissue, thus, contrary to general belief, MDR activity seems not to play a major role in primary drug resistance, but might rather explain preferential/selective activity of Irinotecan and/or Oxaliplatin. Still, this picture might be more complex since chemotherapy by itself might alter MDR activity, and furthermore, today limited data is available about MDR activity of cancer stem cells in colorectal cancers. VIRTUAL SLIDES: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1675739129145824 BioMed Central 2015-04-16 /pmc/articles/PMC4415444/ /pubmed/25885226 http://dx.doi.org/10.1186/s13000-015-0264-6 Text en © Micsik et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Micsik, Tamás Lőrincz, András Mersich, Tamás Baranyai, Zsolt Besznyák, István Dede, Kristóf Zaránd, Attila Jakab, Ferenc Szöllösi, László Krecsák Kéri, György Schwab, Richard Peták, István Decreased functional activity of multidrug resistance protein in primary colorectal cancer |
title | Decreased functional activity of multidrug resistance protein in primary colorectal cancer |
title_full | Decreased functional activity of multidrug resistance protein in primary colorectal cancer |
title_fullStr | Decreased functional activity of multidrug resistance protein in primary colorectal cancer |
title_full_unstemmed | Decreased functional activity of multidrug resistance protein in primary colorectal cancer |
title_short | Decreased functional activity of multidrug resistance protein in primary colorectal cancer |
title_sort | decreased functional activity of multidrug resistance protein in primary colorectal cancer |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4415444/ https://www.ncbi.nlm.nih.gov/pubmed/25885226 http://dx.doi.org/10.1186/s13000-015-0264-6 |
work_keys_str_mv | AT micsiktamas decreasedfunctionalactivityofmultidrugresistanceproteininprimarycolorectalcancer AT lorinczandras decreasedfunctionalactivityofmultidrugresistanceproteininprimarycolorectalcancer AT mersichtamas decreasedfunctionalactivityofmultidrugresistanceproteininprimarycolorectalcancer AT baranyaizsolt decreasedfunctionalactivityofmultidrugresistanceproteininprimarycolorectalcancer AT besznyakistvan decreasedfunctionalactivityofmultidrugresistanceproteininprimarycolorectalcancer AT dedekristof decreasedfunctionalactivityofmultidrugresistanceproteininprimarycolorectalcancer AT zarandattila decreasedfunctionalactivityofmultidrugresistanceproteininprimarycolorectalcancer AT jakabferenc decreasedfunctionalactivityofmultidrugresistanceproteininprimarycolorectalcancer AT szollosilaszlokrecsak decreasedfunctionalactivityofmultidrugresistanceproteininprimarycolorectalcancer AT kerigyorgy decreasedfunctionalactivityofmultidrugresistanceproteininprimarycolorectalcancer AT schwabrichard decreasedfunctionalactivityofmultidrugresistanceproteininprimarycolorectalcancer AT petakistvan decreasedfunctionalactivityofmultidrugresistanceproteininprimarycolorectalcancer |